Navigation Links
Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
Date:6/18/2008

s of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Trofile is a trademark of Monogram Biosciences, Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@ jeremiah.hall@


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
6. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Anaptys Biosciences Raises Over $33 Million in Series B Financing
10. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
(Date:8/21/2014)... care physicians in rural communities do not routinely ... to Penn State medical and public health researchers. ... have limited resources if they seek help., "Rural ... women," said Jennifer S. McCall-Hosenfeld, a primary care ... health sciences, Penn State College of Medicine. "However, ...
(Date:8/21/2014)... August 21, 2014 Xarelto lawsuit ( ... patients to suffer uncontrollable internal bleeding and other serious ... LLP reports. According to court documents, a wrongful death ... Court, Easter District of New York by the family ... bleeding event that was allegedly caused by Xarelto. Among ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... manufactured by Boston Scientific has begun in Massachusetts ... bellwether trial. The Rottenstein Law Group LLP, a ... with claims of harm stemming from the implantation ... claim for compensation for injuries suffered at ...
(Date:8/21/2014)... Annapolis, MD (PRWEB) August 21, 2014 ... real estate organizations to obtain industry-focused data, is ... out healthcare real estate data on the Southeast, ... RevistaMed.com/PropertySearch – the first widely available, ... , The total number of searchable properties, including ...
Breaking Medicine News(10 mins):Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5
... , TUESDAY, Feb. 1 (HealthDay News) -- Many black ... interaction stressful and don,t feel physicians give them enough useful ... suggests. The findings stem from a series of focus ... result: doctors are viewed as coming up short when it ...
... cancer cells dodge the immune system and promote tumor growth, ... disease. While comparable mechanisms to avoid the immune system have ... study tested human breast tumor cells, putting researchers closer to ... The study, published in the journal Cancer Research , ...
... targeted breast biopsies for patients with early breast cancer, ... from undergoing a second breast cancer surgery, a new ... undergo a sentinel lymph node biopsy to determine if ... author of the study. Ultrasound, on its own, ...
... , TUESDAY, Feb. 1 (HealthDay News) -- Finally some good ... with their parents behave better, have stronger mental health and ... study. Researchers at Brigham Young University,s School of Family ... to 16. They found that the most popular video games ...
... screening for breast cancer delivers consistent rates of cancer detection ... study published online and in the April print edition of ... than mammography at identifying suspicious areas of the breast, it ... lesions, which can result in additional testing and false-positive results ...
... published a new international multidisciplinary classification of lung adenocarcinoma, ... The new classification is published in the February ... the official publication of the International Association for the ... rapid advances in lung adenocarcinoma affecting clinical, radiologic, pathologic, ...
Cached Medicine News:Health News:Study Examines Reasons Some Black Men Avoid Doctors 2Health News:Breast cancer cells outsmart the immune system and thrive 2Health News:Breast cancer cells outsmart the immune system and thrive 3Health News:Microbubble ultrasound and breast biopsies 2Health News:Girls Win When They Play Video Games With Parents: Study 2Health News:Repeat MRI screening for breast cancer results in fewer false positives 2Health News:Lung societies unveil new international classification of lung adenocarcinoma 2
(Date:8/21/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced positive results from a randomized, double-blind Phase ... for the treatment of edematous fibrosclerotic panniculopathy (EFP), ... trial, all three doses of CCH (low (0.06mg), ... in the appearance of cellulite as measured by ...
(Date:8/20/2014)... Aug. 20, 2014 The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kansas blocked the sale of more ...
(Date:8/20/2014)... NEW YORK , Aug. 20, ... a new market research report is ... The Market for Hospital-Acquired Infection Control ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... and healthcare-associated infections (HAIs), demand has ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... 2007 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc. announced today multiple ... gadolinium),Injection, including an oral presentation of Phase ... Gadolinium And Radiation,Therapy) trial data. The presentations ... the 2007 American Society of Clinical Oncology,Annual ...
... Potential Benefit of Unique OROS(R),Formulation, SAN DIEGO, ... abuse,remains an ongoing concern for parents and ... Hyperactivity Disorder,(ADHD). Data presented on Tuesday at ... Association highlighted findings that,long-acting OROS(R) methylphenidate had ...
Cached Medicine Technology:Pharmacyclics Announces Presentations and Published Abstracts on,Xcytrin at The 2007 American Society of Clinical Oncology Annual,Meeting 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 3New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 4New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: